News & Updates

Diagnosis, progression, or death due to prostate cancer occur at approximately a decade to 15 years following an initial assessment of prostate-specific antigen (PSA) levels in older men, according to a study presented at EAU 2022.

In men with intermediate- or high-risk prostate cancer (PCa), local failure after definitive radiation therapy (RT) is indicative of survival outcomes, according to a recent study.

Men who regularly consume dairy foods are more likely to develop prostate cancer than those with a lower level of consumption, a prospective cohort study has found.

The anti-PD-L1 antibody avelumab demonstrated clinical activity as first-line treatment for patients with metastatic or locally advanced urothelial carcinoma who were PD-L1-positive and ineligible for cisplatin, according to findings from the ARIES trial presented at EAU 2022.

Patients with bladder cancer suffer from high rates of sexual dysfunction, especially those who have undergone radical treatments, a recent study has found.

The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.